AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25335247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch capsules, 1 capsule orally before sleep for 15 days, 2 sessions total).
Number of subjects: 120
Study 23403549 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐Stop
Number of subjects: 100
Study 23403549 — intervention group
Group type: COMPARATOR
Intervention: Decompression
Number of subjects: 100
Study 23403549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 20132285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 405
Study 20132285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 405
Study 20132285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 17920108 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy using cisplatin/cyclophosphamide or cisplatin/paclitaxel chemotherapy
Number of subjects: 151
Study 16629278 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Patients (SPs)
Number of subjects: 0
Study 16629278 — intervention group
Group type: COMPARATOR
Intervention: Usual method of instruction
Number of subjects: 0
Study 14636967 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 353
Study 14636967 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 353
Study 14636967 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral group counseling
Number of subjects: 353
Study 10651430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron (4 mg)
Number of subjects: 58
Study 10651430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 8862952 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment (850 mg three times daily for 12 weeks)
Number of subjects: 27
Study 8862952 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 27
Study 1308476 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) infusion (600 mg every day for seven days)
Number of subjects: 10
Study 1308476 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) infusion
Number of subjects: 10
Study 1308476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6427827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 11
Study 6427827 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine‐N‐oxide
Number of subjects: 11
Study 6427827 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 11
Study 6427827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 11
Study 6427827 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 11
Study 6427827 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocarboxazide
Number of subjects: 11
Study 6427827 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 11
Study 30878983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 80
Study 30878983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30185210 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 54
Study 30185210 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 54
Study 30185210 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention control
Number of subjects: 54
Study 27228432 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN), n=36
Number of subjects: 69
Study 27228432 — intervention group
Group type: COMPARATOR
Intervention: SHAM treatment, n=33
Number of subjects: 69
Study 24560188 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful weight reduction (n = 20)
Number of subjects: 57
Study 24560188 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful weight reduction (n = 27)
Number of subjects: 57
Study 23131255 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose linezolid treatment for MDR-TB (16 weeks, daily dosage)
Number of subjects: 36
Study 23131255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study 20678686 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of atorvastatin (20 mg)
Number of subjects: 46
Study 20678686 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of atorvastatin (20 mg)
Number of subjects: 46
Study 20678686 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of ortho-hydroxy-atorvastatin (20 mg)
Number of subjects: 46
Study 20678686 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of ortho-hydroxy-atorvastatin (20 mg)
Number of subjects: 46
Study 20678686 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations of atorvastatin
Number of subjects: 46
Study 20678686 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations of ortho-hydroxy-atorvastatin
Number of subjects: 46
Study 17660388 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic infusion of L-NMMA (10 mg/kg)
Number of subjects: 20
Study 15711037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dilution CVVH
Number of subjects: 31
Study 15711037 — intervention group
Group type: COMPARATOR
Intervention: Post-dilution CVVH
Number of subjects: 31
Study 15711037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (NP) pre-filter
Number of subjects: 31
Study 15711037 — intervention group
Group type: COMPARATOR
Intervention: Heparin-protamine (HP) post-filter
Number of subjects: 31
Study 12413113 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video and written instructions
Number of subjects: 500
Study 12413113 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge instructions
Number of subjects: 500
Study 10070942 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening (6 guaiac-impregnated fecal occult blood tests)
Number of subjects: 46551
Study 10070942 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial screening (6 guaiac-impregnated fecal occult blood tests)
Number of subjects: 46551
Study 10070942 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 46551
Study 8849355 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 200 mg/day
Number of subjects: 28
Study 8849355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2339674 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 14
Study 2339674 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 14
Study 2339674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 322562 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate
Number of subjects: 44
Study 31264269 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses with increased compression factor (1.75 D)
Number of subjects: 28
Study 31264269 — intervention group
Group type: COMPARATOR
Intervention: Orthokeratology lenses with lower compression factor (0.75 D)
Number of subjects: 28
Study 31011270 — intervention group
Group type: EXPERIMENTAL
Intervention: 7Ps elements (product, place, promotion, people, physical assets, process management)
Number of subjects: 235
Study 28553094 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard training
Number of subjects: 30
Study 28553094 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype device
Number of subjects: 30
Study 28553094 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 28553094 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard training and Prototype device
Number of subjects: 30
Study 25085109 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-based statistical procedure (SPM)
Number of subjects: 71
Study 25085109 — intervention group
Group type: COMPARATOR
Intervention: Standard visual analysis (SVA)
Number of subjects: 71
Study 23891440 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet enriched with β-hydroxy-β-methylbutirate, calcium, and vitamin D administered during 30 days of hospitalization.
Number of subjects: 100
Study 23891440 — intervention group
Group type: COMPARATOR
Intervention: Control diet administered during 30 days of hospitalization.
Number of subjects: 100
Study 23891440 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet enriched with β-hydroxy-β-methylbutirate, calcium, and vitamin D.
Number of subjects: 100
Study 23891440 — intervention group
Group type: COMPARATOR
Intervention: Control diet.
Number of subjects: 100
Study 21733833 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 0
Study 21733833 — intervention group
Group type: COMPARATOR
Intervention: Social Behaviour and Network Therapy (SBNT)
Number of subjects: 0
Study 19687343 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (ATOR) 80 mg/d for 12 weeks
Number of subjects: 26
Study 19687343 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 26
Study 16544453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led fall prevention program including training nurses in the use of the Morse Fall Scale and implementing 15 selected preventive interventions.
Number of subjects: 409
Study 16544453 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (control).
Number of subjects: 409
Study 12637119 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline alfoscerate (CA) 400 mg capsules, 3 times daily for 180 days
Number of subjects: 261
Study 12637119 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules, 3 times daily for 180 days
Number of subjects: 261
Study 12637119 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline alfoscerate (CA)
Number of subjects: 261
Study 12637119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 10695935 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate (DH)
Number of subjects: 141
Study 10695935 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 141
Study 9198257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 3-week multidisciplinary program
Number of subjects: 123
Study 9198257 — intervention group
Group type: COMPARATOR
Intervention: Active physical training and back school (Program 2)
Number of subjects: 123
Study 9198257 — intervention group
Group type: COMPARATOR
Intervention: Psychological pain management and active physical training (Program 3)
Number of subjects: 123
Study 1287138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 400 mg once daily
Number of subjects: 123
Study 1287138 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav 500 mg three times daily
Number of subjects: 123
Study 1287138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 123
Study 1287138 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 123
Study 3933134 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% mannitol mechanical bowel preparation combined with oral neomycin and short-term, perioperative intravenous Flagyl (group I)
Number of subjects: 68
Study 3933134 — intervention group
Group type: COMPARATOR
Intervention: Oral neomycin and intravenous placebo (group II)
Number of subjects: 68
Study 31064779 — intervention group
Group type: EXPERIMENTAL
Intervention: glasdegib + low-dose cytarabine (LDAC)
Number of subjects: 115
Study 31064779 — intervention group
Group type: COMPARATOR
Intervention: low-dose cytarabine (LDAC) alone
Number of subjects: 115
Study 31064779 — intervention group
Group type: EXPERIMENTAL
Intervention: glasdegib + LDAC
Number of subjects: 115
Study 29050507 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training (twice a week for 12 weeks, load of 50% and 70% of one repetition maximum)
Number of subjects: 60
Study 29050507 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatment (Control Group)
Number of subjects: 60
Study 26580234 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 716
Study 26580234 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 716
Study 26580234 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 716
Study 26580234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 716
Study 24354834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation Consultant (LC) + Electronically Prompted guidance (EP)
Number of subjects: 0
Study 24354834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation Consultant (LC)
Number of subjects: 0
Study 24354834 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study 22277301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 61
Study 22277301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 19857509 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein
Number of subjects: 1533
Study 19857509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1533
Study 16980507 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG + Meloxicam (Melox) 15 mg
Number of subjects: 41
Study 16980507 — intervention group
Group type: COMPARATOR
Intervention: LNG + Placebo
Number of subjects: 41
Study 16253100 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 24
Study 16253100 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + CAF
Number of subjects: 24
Study 16253100 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 12037693 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 55
Study 12037693 — intervention group
Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 55
Study 12037693 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 55
Study 10208561 — intervention group
Group type: EXPERIMENTAL
Intervention: Go trials
Number of subjects: 0
Study 10208561 — intervention group
Group type: EXPERIMENTAL
Intervention: No-go trials
Number of subjects: 0
Study 7774474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense follow-up after curative surgery (clinical examination, rigid proctosigmoidoscopy, colonoscopy, CT of pelvis, pulmonary x-ray, liver function tests, carcinoembryonic antigen, fecal hemoglobin); follow-up duration ranged from 5.5 to 8.8 years.
Number of subjects: 107
Study 7774474 — intervention group
Group type: COMPARATOR
Intervention: Control group with no follow-up; n = 54.
Number of subjects: 107
Study 7774474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense follow-up group; n = 53.
Number of subjects: 107
Study 7774474 — intervention group
Group type: COMPARATOR
Intervention: Control group; n = 54.
Number of subjects: 107
Study 2101381 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-protein rich diet (30% of ideal total calorie requirement)
Number of subjects: 96
Study 2101381 — intervention group
Group type: COMPARATOR
Intervention: Hospital diet (control group)
Number of subjects: 96
Study 7007840 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy with cimetidine (400 mg twice a day)
Number of subjects: 48
Study 7007840 — intervention group
Group type: COMPARATOR
Intervention: Intermittent therapy with cimetidine (six-week courses for each relapse)
Number of subjects: 48
Study 31591903 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (3 times per week at 65%-75% of heart rate max for 45 minutes per session)
Number of subjects: 26
Study 31591903 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 26
Study 30429410 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 384
Study 30429410 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Activity
Number of subjects: 384
Study 30429410 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 384
Study 27893326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine (platinum therapy)
Number of subjects: 648
Study 27893326 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and gemcitabine (nonplatinum therapy)
Number of subjects: 648
Study 27893326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and pemetrexed (platinum therapy)
Number of subjects: 648
Study 27893326 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and pemetrexed (nonplatinum therapy)
Number of subjects: 648
Study 25778467 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK infusion for 12 hours
Number of subjects: 318
Study 23337018 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-resistance training (3 series of 8 to 15RM; nine exercises with 1-3 min rest between sets, three times a week for 8 weeks)
Number of subjects: 2
Study 23337018 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-resistance training
Number of subjects: 2
Study 21834960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 21834960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19619442 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy with adjuvant transcatheter arterial chemoembolization (TACE)
Number of subjects: 108
Study 19619442 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy alone
Number of subjects: 108
Study 18664063 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected specimens
Number of subjects: 878
Study 18664063 — intervention group
Group type: COMPARATOR
Intervention: Provider-collected samples
Number of subjects: 878
Study 18664063 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HPV assessment
Number of subjects: 878
Study 18664063 — intervention group
Group type: COMPARATOR
Intervention: Provider-collected specimens
Number of subjects: 878
Study 18664063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both specimens
Number of subjects: 878
Study 16249701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir monotherapy
Number of subjects: 42
Study 16249701 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir + 2 nucleosides (triple therapy)
Number of subjects: 42
Study 16249701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 16249701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir monotherapy failures
Number of subjects: 42
Study 12072676 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of air from a home humidifier generating O(2)(‐)(H(2)O)(n) for 4 hrs followed by positive ions from a jet nebulizer for 4 hrs
Number of subjects: 20
Study 12072676 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of positive ions for 4 hrs followed by inhalation of air from a home humidifier generating O(2)(‐)(H(2)O)(n) for 4 hrs
Number of subjects: 20
Study 10443658 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analog (Lispro)
Number of subjects: 10
Study 10443658 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (Velosuline)
Number of subjects: 10
Study 7541026 — intervention group
Group type: EXPERIMENTAL
Intervention: SAWA bands of 153, 144, 38 and 32 kDa
Number of subjects: 0
Study 7541026 — intervention group
Group type: EXPERIMENTAL
Intervention: SAWA bands of 144, 38, 32 and 18 kDa
Number of subjects: 0
Study 2085987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FT, 3 g)
Number of subjects: 51
Study 2085987 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim (TMP, 200 mg)
Number of subjects: 51
Study 6107592 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment (antilymphocyte globulin, prednisolone, and azathioprine)
Number of subjects: 30
Study 6107592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30208421 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy (delivered via a light-emitting mask, peak 505 nm, 23 scotopic Td), worn each night for 12 months
Number of subjects: 60
Study 30208421 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 60
Study 30208421 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 60
Study 27670977 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐rTMS
Number of subjects: 8
Study 27670977 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study 24178368 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 240 mg bid
Number of subjects: 52
Study 24178368 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 480 mg bid
Number of subjects: 52
Study 24178368 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 720 mg bid
Number of subjects: 52
Study 24178368 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg bid
Number of subjects: 52
Study 22546036 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention lecture on injury prevention
Number of subjects: 1049
Study 22546036 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 1049
Study 20032275 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual-care-plus-Internet support
Number of subjects: 72
Study 20032275 — intervention group
Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 72
Study 18633177 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once daily
Number of subjects: 163
Study 18633177 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 163
Study 18633177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 15868131 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective roughness scaling by 19 speech and voice therapy students
Number of subjects: 78
Study 15868131 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided measurement of vocal fold cycle irregularity (irregularity index)
Number of subjects: 78
Study 12709818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipamfylline ointment
Number of subjects: 21